{'fraction_non_alphanumeric': 0.02981029810298103, 'fraction_numerical': 0.016260162601626018, 'mean_word_length': 5.881987577639752, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Immunological Evaluation of Co-assembling a Lipidated Peptide Antigen and Lipophilic Adjuvants as Self-adjuvanting Anti-breast Cancer Vaccine Candidates.

We evaluated co-assembling vaccines composed of lipidated HER2-derived antigenic CH401 peptide and a lipophilic adjuvant, Pam 3 CSK 4 , α-GalCer, or lipid A 506, as breast cancer vaccine candidates. This vaccine design was aimed to inherit both antigen multivalency and antigen-specific immunostimulation properties, observed in reported self-adjuvanting vaccine candidates, using self-assembling and adjuvant-conjugated antigens. Under vaccination concentrations, respective lipophilic adjuvants underwent co-assembly with lipidated CH401, which boosted the anti-CH401 IgG and IgM production. In particular, α-GalCer was responsible for the most significant immune activation. Therefore, our newly developed vaccine design enabled the optimization of adjuvants against the antigenic CH401 peptide in a simple preparatory manner. Overall, our co-assembling vaccine design opens the door for efficient and practical self-adjuvanting vaccine development.